31 October 2017
The Cancer Immunotherapy programme has successfully completed the latest round of clinical trials of the novel melanoma vaccine therapy in development at the Malaghan Institute.
“The scientific manuscript describing the results of the Phase I trial has just been accepted in the journal Cancer Immunology, Immunotherapy,” says head of the Translational Immunology programme, Dr Olivier Gasser.
Leading on from the Phase I safety and dosage clinical trial, a research-based Phase II clinical trial is nearing completion. The results, which are scheduled to be collated and interpreted in the beginning of 2018, will provide a great deal of insight Prof Hermans and his team can use towards future work in this project.